A Single use platform for intensified viral vector production
Sponsored by: Sartorius Stedim Biotech
- Viral Vector Based Vaccines
- Upstream Processing
Date: 26 September
Days to go: 40
Time: 3PM London/10AM New York
Accelerate your timelines and develop highly efficient viral vector vaccines processes
Viral vector-based vaccines are a promising field in vaccinology and are taking more importance in the overall vaccine pipeline. They elicit a strong immune response in patients, avoid the use of highly pathogenic viruses – such as Ebola – and most important are “platform-able”. It allows firms to reduce the time and cost of bringing their vaccines to the clinic thus shortening the time to market. However, live-viruses are complex entities to produce and purify. Innovations in the field of bioprocessing, analytics and data management are needed to increase overall productivity, get a better understanding of the process and adapt the platform efficiently to the different indications.
This presentation will first describe how vaccine developers can accelerate their timelines and develop highly efficient viral vector processes by using high throughput fully automatic multi-parallel bioreactor testing tools such as ambr®, DoE software and single-use solutions able to operate with mammalian, insect and avian expression systems.
Upstream process intensification methods, scale-up tools and real case data will be presented for cell culture in fed batch, concentrated fed batch or perfusion mode. We will show how intensifying the working cell bank and the seed train bioreactor with perfusion helps saving half of the consumable costs and reduces the main bioreactor cell expansion time by up to 40%. Coupling the production bioreactor with ATF, inline analyzers and online multivariate process monitoring software further provides 10 to 50 times higher cell density and the full automation and predictive control of the cell culture process performance.
Please register to reserve your spot for this exciting webinar and we look forward to welcoming you to our presentation.
Marketing manager – New Generation Vaccines
Amélie Boulais is Marketing Manager – new generation vaccines – at Sartorius Stedim Biotech. She is analyzing the trends of the vaccine industry in order to define best-in-class solutions with the required associated Process Development support and related services for vaccine applications. She started her collaboration with Sartorius in 2008 and held various positions, supporting and advising actors of the bio-industry in their development from Upstream to final filling operations, with a focus on downstream processing and virus clearance. Amélie is graduated from the ENSTBB (the Biotechnology Engineering institute of Bordeaux, France) and holds a Biotechnology Engineer degree.
Key Learning Objectives
- Understand how process intensification can be applied to viral vector production
- Configure single-use process scale equipment for viral vectors manufacturing
- Discover tools to speed-up process development
- Learn how data analytics can be used for predictive control
- Process Development Scientists
- Process Development Managers
- Process Engineers
- Engineering Directors